Participants in Phase 1 Oncology Research TrialsAre They Vulnerable?
Authors:
- Elizabeth HorstmannEHElizabeth Horstmann
- Ezekiel J. EmanuelEEEzekiel J. Emanuel
- Christine GradyCGChristine Grady
- 14 January 2008
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 168 (1) , 16-20
Abstract
Research from JAMA Internal Medicine — Participants in Phase 1 Oncology Research Trials — Are They Vulnerable?Keywords
This publication has 19 references indexed in Scilit:
- Vulnerable Populations in Research: The Case of the Seriously IllTheoretical Medicine and Bioethics, 2006
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002New England Journal of Medicine, 2005
- The Limitations of “Vulnerability” as a Protection for Human Research ParticipantsThe American Journal of Bioethics, 2004
- People at the End of Life are a Vulnerable Research PopulationClinical Oncology, 2004
- Phase I Cancer Trials: A Collusion of MisunderstandingHastings Center Report, 2000
- Quantitative Analysis of Ethical Issues in Phase I Trials: A Survey Interview Study of 144 Advanced Cancer PatientsIRB: Ethics & Human Research, 2000
- Ethical Issues in the Development of New AgentsInvestigational New Drugs, 1999
- Informed consent for phase I studies: Evaluation of quantity and quality of information provided to patientsAnnals of Oncology, 1995
- Response rates, duration of response, and dose response effects in phase I studies of antineoplasticsInvestigational New Drugs, 1991
- Responses and toxic deaths in Phase I clinical trialsAnnals of Oncology, 1990